| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/31/2003 | WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai |
| 07/31/2003 | WO2002015895A3 Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | WO2001095942A3 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 07/31/2003 | WO2001034566A3 Protease inhibitors |
| 07/31/2003 | US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 07/31/2003 | US20030144525 Conjugated aromatic compounds with a pyridine substituent |
| 07/31/2003 | US20030144523 Epothilone derivatives, method for producing same and their pharmaceutical use |
| 07/31/2003 | US20030144520 Inhibit p38- alpha kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein noninterfering substituent; |
| 07/31/2003 | US20030144510 Preparation of pharmaceutical salts |
| 07/31/2003 | US20030144507 Sulfonamide-containing heterocyclic compounds |
| 07/31/2003 | US20030144495 Drosophila recombination-associated protein and methods for use |
| 07/31/2003 | US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents |
| 07/31/2003 | US20030144360 Synthetic bile acid receptor/ farnesoid x-activated receptor (bar/fxr) ligands agn 29 and agn 31 used as anticholesterol agents |
| 07/31/2003 | US20030144359 Dermatological use and a dermatological preparation |
| 07/31/2003 | US20030144352 Antimuscarinic aerosol |
| 07/31/2003 | US20030144347 Method for treating autoimmune disease |
| 07/31/2003 | US20030144346 Methods and compositions for regulation of 5-alpha reductase activity |
| 07/31/2003 | US20030144343 To treat and/or prevent hypertension, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, and endothelial dysfunction or endothelial damage as a consequence of atherosclerotic processes or diabetes |
| 07/31/2003 | US20030144339 Treatment of inflammatory disease, arthritis, asthma |
| 07/31/2003 | US20030144338 Pyrrole derivative |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144334 Cyclopentabenzofuran derivatives and their use |
| 07/31/2003 | US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals |
| 07/31/2003 | US20030144331 p53 inhibitors and therapeutic use of the same |
| 07/31/2003 | US20030144329 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144327 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
| 07/31/2003 | US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 07/31/2003 | US20030144323 Phenylalkynes |
| 07/31/2003 | US20030144316 Remedies |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144309 Inhibitors of Src and other protein kinases |
| 07/31/2003 | US20030144304 Novel hexacyclic compounds |
| 07/31/2003 | US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144299 Method of treating depression with delta receptor agonist compounds |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144295 A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144289 Dopamine and serotonin reuptake antagonists, used for the prophylaxis of drug abuse or dependence, neurodegenerative diseases or as antidepressants |
| 07/31/2003 | US20030144288 Sulfur compounds such as 4-fluoro-N-(4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl) -benzamide, used as preferential adenosine receptor ligands for the prophylaxis of neurodegenerative disorders |
| 07/31/2003 | US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis |
| 07/31/2003 | US20030144284 Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents |
| 07/31/2003 | US20030144283 Amide substituted imidazoquinolines |
| 07/31/2003 | US20030144281 Substituted benzimidazole compounds |
| 07/31/2003 | US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same |
| 07/31/2003 | US20030144275 Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis |
| 07/31/2003 | US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis |
| 07/31/2003 | US20030144269 Administering an effective amount of vasopeptidase inhibitor such as omapatrilat or gemopatrilat for reducing hypertension |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144265 HIV protease inhibitors based on amino acid derivatives |
| 07/31/2003 | US20030144262 Heteroaryl and heterocyclic nitrogen ring containing hydrazide compounds useful for treating neurodegenerative disorderes |
| 07/31/2003 | US20030144261 A cyclic peptide useful for treating eating disorder and diabetes |
| 07/31/2003 | US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 07/31/2003 | US20030144252 Bicalutamide and N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4 -amine used as inhibitor of prostate cancer |
| 07/31/2003 | US20030144234 Administering a cathepsin modulator or enzyme inhibitor, select from a mRNA or a protein; gene expression inhibition, analgesics |
| 07/31/2003 | US20030144233 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 07/31/2003 | US20030144220 Use of CYP2D6 inhibitors in combination therapies |
| 07/31/2003 | US20030144217 Prodrugs of aspartyl protease inhibitors |
| 07/31/2003 | US20030144209 Bone anabolic agents for the treatment of bone disease |
| 07/31/2003 | US20030144206 Combined use of a GLP-1 compound and modulator of diabetic late complications |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144199 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 07/31/2003 | US20030144197 Autologous growth factor cocktail composition, method of production and use |
| 07/31/2003 | US20030144180 Contains as active ingredient a therapeutically effective amount of agent for either enhancing protein kinase c production and/or activation |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143713 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143683 Introducing a nucleotide sequence encoding prefered amino acid sequences in into a host cell and culturing the host cell in which the peptides are expressed from the nucleotide sequence; human therapeutics and diagnostic protein |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143668 Guanosine triphosphate-binding protein coupled receptors |
| 07/31/2003 | US20030143623 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/31/2003 | US20030143595 Isolated and/or recombinantly produced polypeptide; use in regulating spermatogenesis, cell differentiation and proliferation |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143588 Phosphodiesterases |
| 07/31/2003 | US20030143275 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143269 Tamper-resistant oral opioid agonist formulations |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143232 Incubating survivin and p34cdc2-cyclin B1 kinase complex in presence of an agent; determining whether agent modulates phosphorylation of survivin by p34cdc2-cyclin B1 kinase complex, identifying an agent which modulates phosphorylation |
| 07/31/2003 | US20030143226 For therapy of arteriosclerosis, thrombocytopenia, kidneyd iseases, various types of inflammation such as myocardial ischemic reperfusion injury, inflammatory reactions after percutaneous transluminal coronary recanalization (PTCR)) |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143215 Carbonyl stress-ameliorating agents |
| 07/31/2003 | US20030143207 Remodeling of tissues and organ |
| 07/31/2003 | US20030143198 Method for preparing a physiologically active il-18 polypeptide |
| 07/31/2003 | US20030143197 Administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | US20030143183 Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
| 07/31/2003 | CA2514088A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | CA2511223A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | CA2476984A1 Lactoferrin as an agent for enhancing action of an opioid |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474344A1 Expansion of renewable stem cell populations |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2473884A1 Method of treatment of a patient requiring analgesia |
| 07/31/2003 | CA2473796A1 Substituted quinazolin-4-ylamine analogues |